1
Clinical Trials associated with M2-2 deleted RSV(National Institute of Allergy & Infectious Diseases)A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Live Recombinant RSV D46cpΔM2-2 Vero Grown Virus Vaccine (Lot RSV #008A), Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age
The purpose of this study is to evaluate the safety and immunogenicity of the RSV D46cpΔM2-2 vaccine in RSV-seropositive children and RSV-seronegative infants and children.
100 Clinical Results associated with M2-2 deleted RSV(National Institute of Allergy & Infectious Diseases)
100 Translational Medicine associated with M2-2 deleted RSV(National Institute of Allergy & Infectious Diseases)
100 Patents (Medical) associated with M2-2 deleted RSV(National Institute of Allergy & Infectious Diseases)
100 Deals associated with M2-2 deleted RSV(National Institute of Allergy & Infectious Diseases)